InMed Pharmaceuticals Inc. (OTCMKTS:IMLFF – Get Free Report) shares fell 4.2% on Tuesday . The company traded as low as $0.29 and last traded at $0.31. 784,397 shares traded hands during mid-day trading, an increase of 6,799% from the average session volume of 11,369 shares. The stock had previously closed at $0.32.
InMed Pharmaceuticals Price Performance
The business has a 50-day simple moving average of $0.36 and a two-hundred day simple moving average of $0.42.
InMed Pharmaceuticals Company Profile
InMed Pharmaceuticals Inc, a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain.
See Also
- Five stocks we like better than InMed Pharmaceuticals
- Energy and Oil Stocks Explained
- Silicon Motion Proves That AI in Motion Stays in Motion
- Investing In Automotive Stocks
- Undervalued UnitedHealth Group Won’t Be For Long
- How to Choose Top Rated Stocks
- The 5 Stocks Most Sold By Insiders This Year
Receive News & Ratings for InMed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
